Low back pain

Insights into the Future of Neurology Devices: Exploring the Global Market Report by BCC Research

Retrieved on: 
Thursday, March 28, 2024
Epilepsy, Organization, MRI, Prevalence, Brain, Multiple sclerosis, Data analysis, Neuro, Alzheimer's disease, Nervous system, Patient, Radiosurgery, Research, Spinal cord stimulator, Electrode, Parkinson's disease, Low back pain, Investment, DSM-IV codes, Neurosurgery, Population growth, Ageing, Medical imaging

BOSTON, March 28, 2024 /PRNewswire/ -- According to the latest research study, the demand for Neurology Devices: Global Markets expected to grow from $23.7 billion in 2023 to $31.7 billion by the end of 2028 at a compound annual growth rate (CAGR) of  6.0% from 2023 through 2028.

Key Points: 
  • Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions.
  • The report looks at things like how much these devices are used, where they're used, and how the market for them is growing.
  • This report thoroughly examines the global market for neurology devices, categorizing it by product type and region.
  • Non-surgeons are increasingly performing spinal cord stimulation procedures instead of neurosurgeons due to the rising global burden of low back pain.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Tuesday, March 19, 2024
Health, Brain, Growth, Neurology, Multiple sclerosis, Deficit spending, Seizure, Rehabilitation, Partnership, Patient, Kernel, Internet, Research, Artificial intelligence, Acquisition, Parkinson's disease, Low back pain, Biogen, KMDF, Neurological disorder, DSM-IV codes, Intellectual property, Government, Report, Virtual reality, Medicine, Pharmaceutical industry

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points: 
  • There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
  • While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
  • These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
  • The North American digital health in neurology market is expected to register a large market share in the revenue.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Tuesday, March 19, 2024
Health, Brain, Growth, Neurology, Multiple sclerosis, Deficit spending, Seizure, Rehabilitation, Partnership, Patient, Kernel, Internet, Research, Artificial intelligence, Acquisition, Parkinson's disease, Low back pain, Biogen, KMDF, Neurological disorder, DSM-IV codes, Intellectual property, Government, Report, Virtual reality, Medicine, Pharmaceutical industry

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points: 
  • There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
  • While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
  • These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
  • The North American digital health in neurology market is expected to register a large market share in the revenue.

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain

Retrieved on: 
Thursday, March 7, 2024
Modic, Safety, Disability, Pharmacokinetics, Patient, Pain, Medication, Psychotherapy, Low back pain, Genetically modified bacteria, Pharmaceutical industry

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain

Key Points: 
  • Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
    London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held, clinical stage pharmaceutical company developing an antibiotic formulation for intradiscal injection to treat Chronic Low Back Pain (CLBP) and disability associated with bone oedema (Modic 1), which is caused by bacterial infection, today announces the completion of enrolment of participants into its Phase 1b Modic Trial.
  • CLBP is a leading cause of disability with significant unmet medical need and contributes to the overuse of chronic opioid therapy.
  • The Modic Trial is a placebo-controlled randomised clinical trial assessing the safety and efficacy of PP353 as a treatment for patients with CLBP associated with Modic 1 changes.
  • Dr Steve Ruston, Chief Executive Officer of Persica Pharmaceuticals Ltd, said: “CLBP is a debilitating condition which affects millions of people.

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Retrieved on: 
Monday, March 4, 2024
Paper, Comparison, Algorithm, PD, ACON, Gold standard, Physician, Pain, Surgeon, Discography, International Society, Biomarker, Software as a service, CLARITY, Patient, Canadian International Council, Diagnosis, Low back pain, CO, Research, Medical imaging

BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the publication of the clinical paper, Establishing a Gold Standard for Noninvasive Identification of Painful Lumbar Discs: Prospective Comparison of Magnetic Resonance Spectroscopy vs Low-Pressure Provocation Discography by the International Journal of Spine Surgery, the official scientific journal of the International Society for the Advancement of Spine Surgery (ISASS).

Key Points: 
  • Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons.
  • Low-pressure provocative discography (PD) has served as the gold standard, despite well-documented drawbacks including being highly invasive and presenting difficult-to-interpret results.
  • Achieving a result of 100% sensitivity (5/5 lumbar discs) means that in this study if discography indicates a disc is painful, then Nociscan will also indicate that the disc is painful.
  • We look forward to introducing Nociscan to a growing number of physicians and patients.”
    Access to the publication can be found here.

Filtering The Facts: The Urology Care Foundation Spreads Awareness for National Kidney Month

Retrieved on: 
Friday, March 1, 2024
Urination, Diabetes, Fever, Woman, Anemia, Penis, Workplace, Kidney, Blood, Smoking, Mineral, Hormone, Pain, Weight loss, Infection, Rib, Nausea, Vomiting, Human, Kidney cancer, University, Somatic symptom disorder, AUA, Tobacco, Disease, Urine, Risk factor, Low back pain, Risk, American Urological Association, Salt, Water, Phosphorus

BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.

Key Points: 
  • BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.
  • The kidneys also make hormones that help to keep blood pressure stable, make red blood cells and help keep bones strong.
  • Kidney health deserves equal awareness,” said Dr. Timothy Averch, chair of the Urology Care Foundation’s Kidney and Adrenal Health Committee.
  • For National Kidney Month, the Urology Care Foundation is focusing on information about kidney cancer and kidney stones:
    It is estimated that there will be over 81,000 new kidney cancer cases and over 14,000 cancer deaths in the United States in 2024.

EmergeOrtho--Triangle Region Welcomes Dr. Ryan McCarter

Retrieved on: 
Monday, March 4, 2024
Neck pain, Spine, Quality of life, Raleigh, North Carolina, Fluoroscopy, Rehabilitation, Patient, Spinal stenosis, Physiology, Low back pain, Sports medicine, MRI, Nursing

DURHAM, N.C., March 4, 2024 /PRNewswire/ -- EmergeOrtho—Triangle Region welcomes Dr. Ryan McCarter, a highly esteemed Physical Medicine and Rehabilitation specialist, focusing on Interventional Spine and Musculoskeletal Medicine.

Key Points: 
  • DURHAM, N.C., March 4, 2024 /PRNewswire/ -- EmergeOrtho—Triangle Region welcomes Dr. Ryan McCarter, a highly esteemed Physical Medicine and Rehabilitation specialist, focusing on Interventional Spine and Musculoskeletal Medicine.
  • "I'm excited to join the EmergeOrtho team and contribute to the mission of delivering top-tier orthopedic and musculoskeletal care," said Dr. McCarter.
  • "As a physician, my goal is to empower each patient on their journey to recovery," said Dr. McCarter.
  • To seek pain treatment, schedule an appointment with Dr. Ryan McCarter.

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
Wednesday, January 31, 2024
Education, Ache, Penile cancer, Urethral cancer, Urination, Kidney cancer, Bleeding, Fluid mechanics, Testicular cancer, Heredity, Urethra, Radiation, Back pain, Infection, Bladder cancer, Abdomen, Foreskin, Weight loss, FACS, Fever, Groin, Risk factor, Diet, AUA, Blog, Cancer, HPV, Combustion, Woman, Urethral caruncle, Growth, Papillomaviridae, Prostate cancer, Low back pain, Penis, Urethral diverticulum, Rib, Death, Skin, Blood, Disease, AIDS, Risk, Ejaculation, Smoking, Workplace, UTI, American Urological Association, Male, Scrotum, Pain, Tenderness, MBA, Somatic symptom disorder, Urine, Smoker, GCNIS, Ulcer, Birth control

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.

Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID

Retrieved on: 
Wednesday, January 31, 2024
Paper, Virus, Fibromyalgia, Chronic pain, University, Research, Low back pain, Food and Drug Administration, Faculty, Migraine, Patient, Irritable bowel syndrome, Pain, Endometriosis, Diagnosis, Central nervous system, COVID, Regardless, Doctor of Philosophy, Food, Back pain, Risk, Analytics, Chronic fatigue syndrome, Viral, NDA, Tonix Pharmaceuticals, Pharmaceutical industry

CHATHAM, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates and currently focused on preparing a New Drug Application (NDA) for Tonmya (formerly TNX-102 SL, sublingual cyclobenzaprine HCl) for the management of fibromyalgia, today announced the online publication of a research paper in the Journal Pain. The article titled, “Chronic Overlapping Pain Conditions Increase the Risk of Long COVID Features, Regardless of Acute COVID Status,” by Bergmans, et al. 1, found that patients with pre-existing chronic overlapping pain conditions (COPCs) had an increased risk of being diagnosed with symptoms of Long COVID1. Faculty at the University of Michigan directed the research. Commentary on the article titled, “A step towards better understanding chronic overlapping pain conditions” by Fitzcharles, et al,2 is in the same issue of the journal.

Key Points: 
  • The article titled, “Chronic Overlapping Pain Conditions Increase the Risk of Long COVID Features, Regardless of Acute COVID Status,” by Bergmans, et al.
  • 1, found that patients with pre-existing chronic overlapping pain conditions (COPCs) had an increased risk of being diagnosed with symptoms of Long COVID1.
  • COPCs include fibromyalgia, chronic fatigue syndrome, migraine headache, irritable bowel syndrome, endometriosis and low back pain.
  • “Tonix is studying TNX-102 SL for the management of fibromyalgia (conditionally approved by U.S. Food and Drug Administration as “Tonmya”) and for fibromyalgia-type Long COVID.

Physical Therapists Positioned to Serve as Primary Care Providers Throughout the U.S. Military

Retrieved on: 
Wednesday, January 31, 2024
Therapy, National security, Low back pain, Research, National Defense Authorization Act, Carpal tunnel syndrome, Joint base, Human, Element, Tennis elbow, Physical therapy, Value, DOD, Physical, Defense, Credentialing, Student, APTA, Nursing

ALEXANDRIA, Va., Jan. 31, 2024 /PRNewswire/ -- The American Physical Therapy Association announces that the U.S. Department of Defense will allow physical therapists to serve as primary care providers for neuromusculoskeletal conditions across all military settings. This designation is based on significant DOD analysis and further confirms the value and cost-effectiveness of early intervention physical therapy.

Key Points: 
  • ALEXANDRIA, Va., Jan. 31, 2024 /PRNewswire/ -- The American Physical Therapy Association announces that the U.S. Department of Defense will allow physical therapists to serve as primary care providers for neuromusculoskeletal conditions across all military settings.
  • "The Department of Defense's decision to elevate physical therapists as primary care providers for neuromusculoskeletal conditions is a testament to the effectiveness and efficiency of the physical therapist's role in our military health system," said Congressman Trent Kelly, R-Miss, who was responsible for ensuring that a request for further analysis of taking physical therapy primary care system-wide be included in the 2023 National Defense Authorization Act.
  • "It is entirely feasible for physical therapists to serve in a primary care [neuromusculoskeletal expert] role throughout the DOD," the report states.
  • The American Physical Therapy Association represents more than 100,000 physical therapists, physical therapist assistants, and physical therapy students nationwide.